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Abstract
Isotretinoin, a synthetic oral retinoid that is used against severe nodulocystic acne, has been
associated with various psychiatric side effects such as depression, suicidality and psychotic
symptoms. A great number of reports on its effects have been published since its introduction into
the market. However, a causal relationship has not been established and the link between
isotretinoin use and psychiatric events remains controversial. The present paper reviews the
available evidence regarding the association of isotretinoin and psychiatric side effects. All published
material reporting psychiatric side effects following isotretinoin treatment, including case reports,
case series, reports from adverse drug event reporting systems, prospective surveys and
retrospective case-control studies, are presented. In addition, the neurobiology of the retinoids
and possible biological mechanisms that may lead to psychopathology are described.
Introduction
Retinoids represent a family of compounds that includes
vitamin A, its derivatives and synthetic molecules that are
chemically related to vitamin A. Isotretinoin (13-cis retin-
oic acid) is a synthetic oral retinoid that is used against
severe, recalcitrant, nodulocystic acne, not responding to
other therapies. It was introduced into the market as Accu-
tane, by Hoffman-La Roche, in 1982, mainly in an
attempt to improve biological activity and minimise the
side effects of vitamin A compounds that were used as an
effective acne treatment prior to the development of
isotretinoin. It is also used for a number of other derma-
tological diseases such as psoriasis, ichthyasis, dermato-
logical lesions in systemic lupus erythematosus, in the
prevention of various types of skin cancer, or even as
adjunctive therapy of acute promyelocytic leukemia. The
side effect profile of isotretinoin includes skeletal system
symptoms (arthralgia, osteoporosis), haematological
(pancytopenia), ocular (corneal opacities conjunctivitis,
optic neuritis, cataract) and dermatological symptoms
(mild acne flare, rash, skin peeling, alopecia, photosensi-
tivity) as well as hyperlipidemia [1-3]. Isotretinoin is also
considered highly teratogenic and is classified as US Food
and Drug Administration (FDA) Pregnancy category X [3].
Its use is therefore contraindicated during pregnancy. In
the USA, the FDA has recently introduced the iPledge pro-
gramme in an attempt to minimise the risk of pregnancy
in female patients receiving isotretinoin.
Early after its release on the market, isotretinoin use was
linked with psychiatric side effects such as depression, sui-
cidal ideation and psychosis. The first report of psychiatric
side effects came in 1982 by Meyskens, who had been
using isotretinoin for patients with advanced cancer. He
reported that 25% of his patients developed depressive
symptomatology and suicidality [4]. In 1983, Hazen et al.
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reported depression in 6 of 110 patients treated for acne
or a keratising disorder [5]. During the next few years, a
large number of case reports, case series, reports from the
Adverse Drug Event Reporting Systems (ADERS), some
retrospective and prospective studies were published,
linking isotretinoin with depression and suicidality
(mainly) or even psychotic symptoms. In 2002, the Amer-
ican Academy of Dermatology invited a panel of experts
to participate in a consensus conference, in order to pro-
duce an opinion regarding the safe use of isotretinoin. At
the same time a second panel of experts examined the
available studies on psychiatric side effects. They con-
cluded that there were flaws in the methodology of the
available studies and more scientific data was needed to
draw conclusions about psychological effects. They also
stated that there is not enough basic science literature
about the effects of retinoids on adult brain function.
The objective of this study was to review available evi-
dence regarding the association of isotretinoin and psy-
chopathology.
Literature search
We searched the MEDLINE and EMBASE databases for
papers published from 1982 until March 2008 reporting
psychiatric side effects following isotretinoin treatment.
Keywords used were: 'isotretinoin', '13-cis retinoic acid',
'psychiatric', 'depression', 'affective', 'suicide', 'psychosis'
and 'violence'. In addition, the reference sections of the
identified papers and main reviews were screened.
Furthermore, several basic science papers providing evi-
dence for potential implication of the retinoids in the eti-
opathogenesis of major psychiatric disorders were
reviewed.
Outcome of the literature search
A great number of single case reports, case series and
reports from ADERS were found. Tables 1, 2 and 3 sum-
marise these reports [4-28]. As shown in the tables, there
are consistent ADERS reports of depression, suicide
attempts, psychosis and aggression associated with
isotretinoin use from many countries. The most compel-
ling data come from the FDA in the USA where 4,992
cases of various psychiatric side effects were reported dur-
ing the period from 1982 till August 2004, including 192
suicide attempts. It should be mentioned that isotretinoin
ranked 4th in the top 10 of all drugs in the FDA database
that were associated with a risk of depression as a side
effect. In addition, psychiatric side effects are consistently
higher for isotretinoin than for other acne treatments as
reported by the World Health Organization in 1998
(Table 4).
Furthermore, a number of retrospective and prospective
studies outlined below were located.
Retrospective studies
Jick et al. published a retrospective cohort study using the
Saskatchewan and UK public health data bases [29]. Their
study included 7,195 isotretinoin users in Saskatchewan
and 340 in UK and 13,700 antibiotic users in Saskatch-
ewan and 676 in the UK. They compared the psychiatric
adverse effects between the isotretinoin and antibiotic
users and also in the isotretinoin users alone pre and post
treatment. The authors found no differences in the relative
risk for depression and psychosis between the isotretinoin
and antibiotic users. They also found no difference in the
relative risk of completed suicide or attempts between the
two groups in the Saskatchewan sample, whereas in the
UK sample only one suicide attempt was reported (too
few to draw a conclusion for relative risk). No difference
was found in the incidence of psychiatric side effects for
the isotretinoin users before and after treatment. It should
be mentioned that this study was criticised for underesti-
mating depression.
Table 1: Case reports linking isotretinoin and psychiatric side effects
Reference Year No. of patients Psychiatric adverse effect
Lindemayr [6] 1986 1 Suicide attempt
Burkett and Storrs [7] 1987 1 Depressive mood
Villalobos et al. [8] 1989 1 Psychosis
Hepburn [9] 1990 1 Suicide attempt
Gatti and Serri [10] 1991 1 Depression/suicide attempt
Aubin et al. [11] 1995 1 Suicide attempt
Cotterill and Cunliffe [12] 1997 1 Depression/suicide attempt
Cott and Wissner [13] 1999 1 Bipolar disorder
Middelkoop [14] 1998 1 Depression/suicide attempt
Ng et al. [15] 2001 1 Depression/suicide attempt
Poblete AC et al. [16] 2006 1 Panic attacks
Bachmann et al. [17] 2007 1 Depression/suicidal ideationAnnals of General Psychiatry 2009, 8:2 http://www.annals-general-psychiatry.com/content/8/1/2
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In a prescription analysis conducted in 2,281 patients
identified in a database as having taken isotretinoin or an
antidepressant it was found that patients receiving
isotretinoin were no more likely to take an antidepressant
[30].
The United Health Care Study found a statistically signif-
icant increase in depression in isotretinoin users when
depression was defined as the coding for diagnosis and/or
antidepressant medication use [31].
Mental health services utilisation was retrospectively stud-
ied in the members of the Israeli defence forces [32]. The
study included 1,419 patients treated with isotretinoin
and 1,102 patients with psoriasis who received other
treatments. The mental health services utilisation in the
isotretinoin group was 17.2% vs 12.5% in the psoriasis
group, a difference that was considered statistically signif-
icant.
The first controlled study to find a statistically significant
association between isotretinoin and depression was
recently published [33]. This case-crossover study investi-
gated a first diagnosis or hospitalisation for depression
and antidepressant treatment prescription in 30,496 sub-
jects who received isotretinoin therapy from 1984 to
2003. Those who received an antidepressant in the 12
months prior to the diagnosis of depression were
excluded; 126 (0.4%) cases met inclusion criteria for
depression. Exposure to isotretinoin in a 5-month risk
period immediately prior to the diagnosis of depression
was compared to a 5-month control period separated
from the risk period by a 2-month 'washout' period. The
number of cases exposed to isotretinoin in the 5-month
risk and control periods were 41 (32.5%) and 28 (22.2%),
respectively. The adjusted relative risk of isotretinoin asso-
ciated with depression was 2.68.
Prospective studies
Hull and Demkiw-Bartel [34] studied 121 patients treated
with isotretinoin and found evidence of depression in 5 of
them that persisted during the course of treatment.
Chia et al. [35] studied 132 patients with moderate to
severe acne treated with isotretinoin or an antibiotic. The
patients were assessed for depression before and after
treatment. The authors found no differences after the
treatment between the two groups.
The relationship between isotretinoin and depression was
studied in a controlled cohort study [36]. Depression was
assessed at baseline and after 2 months of treatment in 2
groups of patients, one receiving isotretinoin (n = 100)
and the other receiving an oral (n = 41) or topical (n = 59)
antibiotic (control group). No correlation between
isotretinoin use and the development of depression was
found.
It is worth noting that a potential source of confusion in
the aforementioned clinical reports is that dermatological
disease itself is considered by many authors a risk factor
for depressive symptoms. Acne has been associated with
depression, suicidal ideation and other psychological
problems such as anxiety, embarrassment and low self-
esteem [37-39]. Others have considered the psychiatric
Table 2: Case series linking isotretinoin and psychiatric side effects
Reference Year No. of patients Psychiatric adverse effect
Meyskens [4] 1982 2 Psychological changes
Hazen et al. [5] 1983 6 Depression
Bruno et al. [18] 1984 22 Depressive symptoms
Bigby and Stern [19] 1983 3 Depression/violent behaviour
Scheinman et al. [20] 1990 7 Depression: suicide attempt (1)
Duke and Guenther [21] 1993 2 Depression
Bravard et al. [22] 1993 3 Depression: suicide attempts (2)
Byrne et al. [23] 1998 3 Depression: suicide attempt (1)
Barak et al. [24] 2005 5 Affective psychosis/suicide attempts (3)
Table 3: Adverse drug event reports linking isotretinoin and psychiatric side effects
Reference Year No. of patients Psychiatric adverse effect
US Food and Drug Administration [25] 1982 to 2004 4,992 Various psychiatric side effects: 192 suicide attempts
Canada [26] 1983 to 2003 56 Depression
UK [27] 1982 to 2006 463 Suspected psychiatric events: 25 completed suicides
Australia [28] 1985 to 1988 12 Depression: Suicide attempts (2)Annals of General Psychiatry 2009, 8:2 http://www.annals-general-psychiatry.com/content/8/1/2
Page 4 of 8
(page number not for citation purposes)
side effects as an idiosyncratic reaction to isotretinoin
[40].
Discussion
In order to establish a causal relationship between a drug
and an adverse effect, a temporal relationship between
drug administration and the onset of the adverse effect is
necessary. Positive cases of challenge, de-challenge and re-
challenge with the drug and plausibility for a biological
role are also important for this association.
According to the Diagnostic and Statistical Manual of
Mental Disorders version 4 text revision (DSM-IV-TR)
diagnostic criteria, a diagnosis of substance-induced
mood or psychotic disorder can be made if the symptoms
develop during or within a month of substance intoxica-
tion or withdrawal. In addition, the symptoms must not
precede the onset of the substance use and must not be
substantially in excess of what would be expected given
the type or amount of the substance used or the duration
of use [41]. If there is a history of non-substance-induced
mood or psychotic disorder, the diagnosis is doubtful.
Most of the authors reporting single cases describe the
onset of psychiatric side effects within 1 month of the
beginning of treatment with isotretinoin. However,
depression, in specific, has been reported as early as 1 day
and up to 4 months after initiating isotretinoin treatment
[5,7,10,12,14,15,17,18,20-23,34]. Dr Marilyn Pitts, a
former safety evaluator for the FDA, reported 41 cases of
positive de-challenge and re-challenge between 1982 and
1998 [42]. Of these, 28 were depressed, 5 were psychotic,
5 had an unspecified mood disorder and 3 had suicidal
ideation.
Studies with animal models also indicate that exposure to
isotretinoin may result in depressive-like behaviour,
although the results in this area are controversial. Finally,
there is biological evidence that retinoids in general can
influence the central nervous system (CNS) and in partic-
ular neuronal development, neurotransmitters and sys-
tems known to be involved in the pathogenesis of
psychiatric disorders.
Preliminary evidence for toxic effects of retinoids on the
CNS comes from hypervitaminosis A, a toxic condition
caused by the excess intake of vitamin A. Vitamin A is one
of the fat soluble vitamins. It can be found in nature in
various forms. In foods of animal origin the main forms
are an alcohol (retinol), an aldehyde (retinal) or an acid
(retinoic acid, RA). Precursors of the vitamin, called pro-
vitamins, are present in foods of plant origin and most of
them belong to the carotenoids. There are over 600 caro-
tenoids in nature and approximately 50 of them can be
metabolised to Vitamin A [43]. β-Carotene is the most
prevalent carotenoid in the food supply that has provita-
min A activity. Retinol, the main form of vitamin A, is
converted into retinyl esters in the small intestine and
then further metabolised to retinol. Retinol is then
inserted into chylomicrons for transport to the liver where
it can be hydrolysed back to retinal when required. The
utilisation of retinol in the peripheral tissues requires the
irreversible conversion to retinoic acid. The majority of
vitamin A effects are mediated by retinoic acid, which
binds to receptors of the nuclear receptor superfamily and
regulates gene expression [44]. Retinal is the essential
form of vitamin A required for normal vision. Vitamin A
(in the form of retinoic acid) has also an important role in
the normal functioning of the immune system, especially
T cell mediated immunity and natural killer activity. In
the developing fetus, vitamin A is essential for normal
morphogenesis, growth and cell differentiation. Hypervi-
taminosis A was first noted in the 16th century by Arctic
explorers who ate polar bear liver or seal liver [45]. They
reported symptoms of drowsiness, irritability, severe
headaches, nausea and 'irrational' behaviour. In 1943,
Rodahl and Moore attributed the polar bear liver toxicity
to the large amounts of vitamin A ingested (13,000 IU to
18,000 IU/g: the maximum non-toxic daily intake is
10,000 IU) [46]. This hypothesis was confirmed by scien-
tists using laboratory animals.
Table 4: Number of cases of suicide, attempted suicide and suicide ideation associated with acne medications.
Acne medication Period Suicide Suicide attempt Suicide ideation Total Estimated patient 
exposure
Adverse drug 
reactions per 
million
Dianette 1980 to 1998 - 3 - 3
Doxycycline 1965 to 1998 - 0 - 0
Minocycline 1971 to 1998 - 2 - 2
Oxytetracycline 1965 to 1998 - 0 - 0
Tetracycline 1964 to 1998 - 3 - 3
Total combined - 8 - 8 300 million 0.03
Roaccutane 1982 to 1998 47 67 56 170 6 million 28.34
Source: World Health Organization, 1998Annals of General Psychiatry 2009, 8:2 http://www.annals-general-psychiatry.com/content/8/1/2
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The reports of the European explorers of the North Pole
describing emotional aberrations among the indigenous
populations seem relevant. In their reports, an explosive
outburst was described, which was named Pibloktoq by the
Inuit Eskimos and referred to by other names in Siberia
and elsewhere. In its classical description, Pibloktoq  is
characterised by a prodromal period of hours or days dur-
ing which the person seems to be mildly irritable or with-
drawn. Then, the person becomes wildly excited, starts
shouting with no cause, tearing off clothes, throwing
objects, mimicking screams of birds or animals and run-
ning frantically onto the tundra or ice pack placing him/
herself in considerable danger. Sometimes, convulsive sei-
zures may follow and finally stuporous sleep or coma last-
ing for up to 12 h. Amnesia for the experience is usually
reported by the victims. Although Pibloktoq is a culture-
bound syndrome, there are cases in which hypervitamino-
sis A has been hypothesised to be the underlying cause
[45,47].
The entity of hypervitaminosis A is today unquestionable.
It is caused by overconsumption of preformed vitamin A
and not carotenoids, which are considered safe. Acute tox-
icity is relatively rare and is seen after administration of
150 mg in adults and 100 mg in children [43]. Symptoms
include irritability, headache, nausea, vomiting, diplopia
(due to increased intracranial pressure), seizures and exfo-
liative dermatitis [45].
Chronic vitamin A intoxication is seen in adults who
ingest 15 mg/daily of vitamin A for a period of several
months and in children who ingest 6 mg/daily [43]. The
clinical manifestations include dry skin, glossitis, alo-
pecia, hyperlipidemia, bone pain, increased intracranial
pressure with headaches, diplopia, papilledema, irritabil-
ity, fatigue, loss of energy, loss of interest, depression and
sometimes psychotic symptoms [45].
The research in the effects of retinoic acid on the CNS has
focused on the developing brain after the observation that
isotretinoin (13-cis retinoic acid) is highly teratogenic for
the CNS. Exposure of the fetus to the drug may cause a
large number of birth defects, several of which involve the
CNS (exencephaly, prosencephaly, hydrocephalus). More
recent work, however, has suggested that retinoic acid
may influence the adult brain as well [48,49]. This
research is relevant to the reports of psychiatric symptoms
in acne patients treated with isotretinoin.
A fundamental role of retinoic acid is the regulation of cell
proliferation and differentiation via the regulation of gene
transcription [50]. In the embryo this is important for the
control of growth of many organs and systems, including
the CNS. These functions are carried over into the adult,
where the retinoic acid controls the proliferation and dif-
ferentiation of the cells of the respiratory, urinary and
intestinal tracts, the bones and the skin. Retinoic acid in
these cells is obtained from the plasma retinol after oxidi-
sation to retinaldehyde and then further oxidisation to
retinoic acid. Retinoic acid then enters the nucleus and
binds to retinoic acid receptors to activate gene transcrip-
tion. Two families of receptors, retinoic acid receptors
(RARs) and retinoid X receptors (RXRs), are active in retin-
oid-mediated gene transcription. Retinoid receptors regu-
late transcription by binding as dimeric complexes to
specific DNA sites, the retinoic acid response elements, in
target genes. The receptors can either stimulate or repress
gene expression in response to their ligands. RAR binds
all-trans retinoic acid and 9-cis retinoic acid, whereas RXR
binds only 9-cis retinoic acid. The RXR receptors can act
independently of ligand, (that is, ligand activation may
not be necessary for the function of this receptor). 13-cis
Retinoic acid (isotretinoin) binds weakly to the RA recep-
tors. However, there is evidence that 13-cis retinoic acid is
isomerised to all-trans retinoic acid in tissues and thus
acts like all-trans retinoic acid to regulate transcription via
the RA receptors [51]. RA receptors are distributed widely
in the adult brain [48,49]. However, RA itself is much less
widely distributed [52]. The regions of the brain that
exhibit RA signalling include the limbic system, in partic-
ular the hippocampus and the medial prefrontal cortex,
the cingulate cortex and subregions of the thalamus and
hypothalamus [48,49].
Recent data have demonstrated that the hippocampus is
one of the brain regions where new neurons are con-
stantly born. This is a phenomenon called neurogenesis.
One of the theories for the pathogenesis of depression
suggests a decreased hippocampal and prefrontal cortex
neurogenesis [53,54]. Antidepressant treatment seems to
lead to an increase in neurogenesis, which is chronologi-
cally seen during the same period as the clinical improve-
ment. Another irregularity in the hippocampus associated
with depression is the reduction of the hippocampal vol-
ume, a finding that is correlated with prognosis (as meas-
ured by the number of hospitalisations and number of
days with depression). The treatment of mice with retin-
oic acid results in both decreased hippocampal neurogen-
esis and a reduction in the hippocampal volume [55,56].
Therefore, if the effect of RA on hippocampal neurogene-
sis is replicated in humans, this could provide a plausible
biological mechanism mediating RA's depressogenic
effects.
Recent quantitative analyses have demonstrated that the
concentrations of retinoic acid in the adult brain are
higher in the striatum and the nucleus accumbens, in a
way similar to dopamine. The enzyme retinaldehyde
dehydrogenase 1 (RALDH1) which is present in the
dopaminergic terminals that innervate the striatum fromAnnals of General Psychiatry 2009, 8:2 http://www.annals-general-psychiatry.com/content/8/1/2
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the ventral tegmental area is necessary for the synthesis of
RA in these areas. In addition, RA seems to modulate the
action of dopamine by regulating the D2 receptor [57].
Krezel et al. [57] reported that in adult mice, single and
compound null mutations in the genes for specific retin-
oic acid receptors (RARβ and RXRβ and γ) resulted in loco-
motor defects related to dysfunction of the mesolimbic
dopaminergic signalling pathway. The expression of D1
and D2 receptors was reduced in the ventral striatum of
mutant mice and the response of double null mutant mice
to cocaine, which affects dopamine signalling in the mes-
olimbic system, was blunted. The authors concluded that
retinoic acid signalling defects may contribute to patholo-
gies such as Parkinson disease and schizophrenia.
Goodman described three lines of evidence suggesting
that retinoids may be implicated in the pathogenesis of
schizophrenia [58]. First, several manifestations similar to
those caused by retinoid dysfunction are found in patients
with schizophrenia and their relatives. These manifesta-
tions include thought disorder, enlarged ventricles, agen-
esis of the corpus callosum and microcephaly. The second
line of evidence implicating retinoids in the genetic aeti-
ology of schizophrenia is the occurrence of known genetic
markers in schizophrenia (candidate susceptibility genes),
which happen to be loci of retinoid pathways or meta-
bolic cascades (such as 6p22, 22q12-13). Finally, the tran-
scriptional activation of dopamine D2 receptor and other
schizophrenia candidate genes, such as the glutamate
receptors, is regulated by retinoic acid. In a more recent
work by Rioux and Arnold [59] it was reported that the
expression of retinoic acid receptor α is increased twofold
in the granule cells of the dentate gyrus in schizophrenia.
The authors concluded that the evidence provided sup-
ports the hypothesis that retinoid pathway dysregulation
may be an important factor in the aetiology of the disease.
Apart from schizophrenia, dopamine has also been impli-
cated in depression. The dopamine hypothesis of depres-
sion supports a diminished dopaminergic
neurotransmission mainly in the prefrontal cortex. Psy-
chomotor retardation, lack of motivation, and inability to
concentrate and experience pleasure are the prominent
features of depression linked with reduced dopamine
transmission [60]. Retinoic acid increases the expression
of genes involved in dopamine signal transduction. There-
fore, the direction of its effect is the opposite of what
would be expected for an agent that promotes depression.
It is hypothesised, however, that an initial induction of
the dopaminergic system results over time in negative
feedback and a long-term decline in some elements of
dopaminergic transmission. It is interesting, though, that
in postmortem brains of suicide victims treated with anti-
depressants, the D2 receptor is higher in number but
'lower' in ligand affinity. It is possible that the retinoic
acid induction of the D2 receptor may result in a greater
number of receptors with lower ligand affinity.
The evidence regarding the effects of retinoic acid in the
serotonin pathways is controversial. In 1991, Ruiz et al.
[61] showed that retinoic acid changes the expression of
serotonin in the developing hindbrain. The application of
low concentration of retinoic acid to Xenopus embryos
resulted in an ectopic location of serotonergic neurons
and an increase in their number. More intermediate or
higher doses resulted in a decrease or complete loss of ser-
otonergic neurons, respectively.
In 2006, O'Reilly et al. [62] showed that the chronic
administration of 13-cis retinoic acid increases depres-
sion-related behaviour in mice, whereas Ferguson et al.
[63], in 2007, reported that the oral treatment with 13-cis
retinoic acid does not increase measures of anhedonia or
depression in rats. In a more recent paper by O'Reilly et al.
[64], 13-cis retinoic acid was found to increase 5-HT1A
receptor and serotonin reuptake transporter levels in vitro;
the authors concluded that this may lead to decreased
serotonin availability at synapses.
Bremner et al. [65] used PET scans to assess the effects of
isotretinoin on brain functioning. This study included 28
treatment-resistant acne patients, as defined by a failed 3-
month antibiotic trial. The patients were not randomly
assigned to treatment with isotretinoin or placebo.
Instead they had decided with their doctors to take either
a second trial of an antibiotic or isotretinoin. Each patient
received a PET scan at baseline and again after 4 months
of treatment with an antibiotic (n = 15) or isotretinoin (n
= 13). Isotretinoin but not antibiotic treatment was asso-
ciated with decreased brain metabolism in the orbitofron-
tal cortex, a brain area known to mediate symptoms of
depression. There were no differences, however, in the
severity of depressive symptoms between the two groups
before and after treatment. Retinoids may lead to a
decrease in orbitofrontal functioning via their effect on
the hippocampus. The hippocampus modulates
dopaminergic function in the medial prefrontal cortex
and RA-induced deficits in hippocampal function may
lead to a downstream effect on orbitofrontal function.
Conclusion
The evidence described in this review strongly suggests a
link between the use of isotretinoin and psychopathology.
There is a great number of reports that support this asso-
ciation. Interestingly, isotretinoin is the only non-psycho-
tropic drug in the FDA's top 10 list of drugs associated
with depression. By contrast, the absence of double-blind,
placebo-controlled studies, some flaws in the methodol-
ogy of the current literature and some contradictingAnnals of General Psychiatry 2009, 8:2 http://www.annals-general-psychiatry.com/content/8/1/2
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results in the studies of animal models seem to be the
major reasons for the lack of an established causal link
between isotretinoin use and psychiatric symptoms. How-
ever, given all the evidence, the association between
isotretinoin use and psychopathology seems most likely
to be justified. The multiformity of reported psychiatric
adverse events (depression, suicide, psychosis) is proba-
bly associated with the multiplicity of isotretinoin's effects
on various neurotransmitter systems and with the various
types of vulnerability of the exposed individuals. There-
fore, clinicians should be on the alert for potential psychi-
atric side effects following treatment with isotretinoin,
especially in vulnerable populations.
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